01 June 2024
Auvelity, a relatively new drug marketed by US pharamceutical company Axsome has already been used to treat 72,000 people suffering depression, reports Andy Extance in
The Observer. It is a combination of the psychedelic compound dextromethorphan and buproprion, which inhibits its hallucinogenic effects.
While the therapeutic mechanism isn't entirely clear, it's believed that the growth of prefrontal cortex neurons triggered by psychedelics may lie at the heart of the success of this form of drug. Read the full story on
The Guardian website.